Table 1.
Descriptive findings of the randomized controlled trials included.
| Magnesium | Placebo | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author, Year | Country | Condition | Inflammatory Parameters | Daily Mg Doses (mg) |
Type of Mg | Follow-Up (Weeks) | Sample Size | Age (SD) (Years) | Women (%) | BMI (SD) |
Sample Size | Age (SD) (Years) | Women (%) | BMI (SD) |
| Alonso, 2020 [34] | USA | Cardiovascular Diseases |
CRP, NO, TAC, GSH, MDA, Tartrate-resistant acid phosphatase type 5, ST2 protein, Interleukin-1 receptor type 1 | 400 | Oxide | 10 | 24 | 62 ± 5 | 88 | 28.3 ± 5.01 | 28 | 62 ± 6 | 61 | 27.8 ± 4.2 |
| Asemi, 2015 [17] | Iran | Pregnancy | CRP, NO, TAC, MDA | 250 | Oxide | 6 | 35 | 29.1 ± 4.6 | 100 | 29.6 ± 5.4 | 35 | 29.4 ± 3.1 | 100 | 29.1 ± 3.5 |
| Chacko, 2010 [25] | USA | Overweight | CRP, IL-6, TNF-alfa | 500 | Citrate | 4 | 13 | 47 ± 13.8 | 43 | 28.3 ± 1.6 | 13 | 41.9 ± 12.7 | 24 | 28.1 ± 2.2 |
| Cosaro, 2014 [28] | Italy | Family history of metabolic syndrome |
CRP | 368 | Pidolate | 8 | 8 | 6 | ||||||
| Hosseini, 2016 [37] | Iran | Asthma | IL-17 | 340 | Citrate | 8 | 50 | 36.38 ± 9.72 | 50 | 25.6 ± 3.8 | 50 | 34.56 ± 8.28 | 44 | 26.19 ± 3.69 |
| Joris, 2017 [31] | The Netherlands | Overweight/ obese |
CRP, IL-6, IL-8, TNF-alfa, amyloid | 350 | Citrate | 24 | 26 | 25 | ||||||
| Kazaks, 2010 [24] | USA | Asthma | CRP | 340 | Citrate | 26 | 27 | 37 ± 2 | 50 | 29 ± 1 | 25 | 37 ± 2 | 61.1 | 28 ± 1 |
| Lima de Souza E Silva, 2014 [29] |
Brasil | Metabolic Syndrome | CRP | 400 | Chelate | 12 | 35 | 44.6 ± 9.7 | 35.5 ± 8.2 | 37 | 46.6 ± 12.3 | 35.1 ± 6.3 | ||
| Mortazavi, 2013 [27] | USA | Hemodialysis patients | CRP | 440 | Oxide | 24 | 27 | 56.93 ± 12.19 | 48.3 | 25 | 56.36 ± 11.15 | 48 | ||
| Moslehi, 2012 [36] | Iran | Overweight | CRP, IL-6, fibrinogen | 250 | Oxide | 8 | 35 | 100 | 27.9 ± 3.2 | 34 | 100 | 27.9 ± 3 | ||
| Mousavi, 2021 [39] | Iran | Polycystic ovary syndrome | CRP, TAC, MDA, TNF-alfa | 250 | Oxide | 8 | 21 | 25.6 ± 4.9 | 100 | 28.0 ± 3.2 | 20 | 26.2 ± 5.7 | 100 | 26.9 ± 3.8 |
| Razzaghi, 2018 [32] | Iran | Diabetic foot ulcer | CRP, NO, TAC, GSH, MDA, ERS | 250 | Oxide | 12 | 35 | 60.1 ± 11.1 | 37.1 | 28.2 ± 5.2 | 35 | 59 ± 10.1 | 31.4 | 26.3 ± 4.2 |
| Rodriguez-Hernandez, 2010 [35] | Mexico | Obese | CRP | 450 | Chloride | 16 | 19 | 44.2 ± 10.8 | 63.6 | 30.5 ± 4.4 | 19 | 43.2 ± 7.8 | 63.6 | 35.1 ± 7.9 |
| Simental-Mendia, 2012 [26] | Mexico | Prediabetes | CRP, IL-6, IL-10, TNF-alfa | 382 | Chloride | 12 | 11 | 44.2 ± 10.8 | 63.6 | 30.5 ± 4.4 | 11 | 43.2 ± 7.8 | 63.6 | 35.1 ± 7.9 |
| Simental-Mendia, 2014 [30] | Mexico | Prediabetes | CRP | 382 | Chloride | 12 | 29 | 39.8 ± 16 | 55.2 | 30.5 ± 5.7 | 28 | 41.1 ± 13.1 | 60.7 | 30 ± 5.7 |
| Talari, 2019 [33] | Iran | Diabetic hemodialysis |
CRP, NO, TAC, GSH, MDA | 250 | Oxide | 24 | 27 | 58.8 ± 10.1 | 51.9 | 27.2 ± 5.6 | 27 | 61.8 ± 10.2 | 55.6 | 26.2 ± 4.4 |
| Zanforlini, 2021 [38] | Italy | Chronic obstructive pulmonary disease |
CRP, TNF-alfa | 300 | Citrate | 24 | 21 | 73 ± 8.9 | 24 | 26.9 ± 4.3 | 20 | 72.2 ± 11 | 20.8 | 26.9 ± 3.8 |
| Total | Median = 12 | 447 | 47.1 ± 9.3 | 62.5 | 29.0 ± 4.4 | 442 | 46.8 ± 8.7 | 59.6 | 29.2 ± 4.4 | |||||